Tan X, et al. - Different pharmacological agents, including abaloparatide and romosozumab, for treatment of osteoporosis in postmenopausal women, were compared regarding their effectiveness and safety. Searching PubMed, Embase, the Cochrane Central Register of Controlled Trials, and Google Scholar, researchers identified 21 records for inclusion in quantitative synthesis; all of these records were of high quality. The analysis suggests that for preventing new vertebral and nonvertebral fractures in postmenopausal women with osteoporosis, abaloparatide and teriparatide were most efficacious, whereas in preventing clinical fractures, zoledronic acid and romosozumab were most efficacious. In terms of safety, abaloparatide, teriparatide or romosozumab, and placebo had no statistical differences. Moreover, in terms of adverse events, statistically worse outcomes were reported in correlation with zoledronic acid vs placebo, and denosumab and romosozumab were reported to be the two of the best interventions, of which denosumab also reduces the risk of different kinds of fractures.